Atrial antitachycardia pacing and managed ventricular pacing in bradycardia patients with paroxysmal or persistent atrial tachyarrhythmias: The MINERVA randomized multicentre international trial

Giuseppe Boriani, Raymond Tukkie, Antonis S. Manolis, Lluis Mont, Helmut Pürerfellner, Massimo Santini, Giuseppe Inama, Paolo Serra, João De Sousa, Giovanni Luca Botto, Lorenza Mangoni, Andrea Grammatico, Luigi Padeletti

Research output: Contribution to journalArticle

Abstract

Aims Atrial fibrillation (AF) is a common comorbidity in bradycardia patients. Advanced pacemakers feature atrial preventive pacing and atrial antitachycardia pacing (DDDRP) and managed ventricular pacing (MVP), which minimizes unnecessary right ventricular pacing.We evaluated whether DDDRP and MVP might reduce mortality, morbidity, or progression to permanent AF when compared with standard dual-chamber pacing (Control DDDR).

Methods and results In a randomized, parallel, single-blind, multi-centre trial we enrolled 1300 patients with bradycardia and previous atrial tachyarrhythmias, in whom a DDDRP pacemaker had recently been implanted. History of permanent AF and thirddegree atrioventricular block were exclusion criteria. After a 1-month run-in period, 1166 eligible patients, aged 74+9 years, 50% females, were randomized to Control DDDR, DDDRP + MVP, or MVP. Analysis was intention-to-treat. The primary outcome, i.e. the 2-year incidence of a combined endpoint composed of death, cardiovascular hospitalizations, or permanent AF, occurred in 102/385 (26.5%) Control DDDR patients, in 76/383 (19.8%) DDDRP + MVP patients [hazard ratio (HR) = 0.74, 95% confidence interval 0.55-0.99, P = 0.04 vs. Control DDDR] and in 85/398 (21.4%) MVP patients (HR = 0.89, 95% confidence interval 0.77-1.03, P = 0.125 vs. Control DDDR). When compared with Control DDDR, DDDRP + MVP reduced the risk for AF longer than 1 day (HR = 0.66, 95% CI 0.52-0.85, P, 0.001), AF longer than 7 days (HR = 0.52, 95% CI 0.36-0.73, P, 0.001), and permanent AF (HR = 0.39, 95% CI 0.21-0.75, P = 0.004).

Conclusion In patients with bradycardia and atrial tachyarrhythmias, DDDRP + MVP is superior to standard dual-chamber pacing. The primary endpoint was significantly lowered through the reduction of the progression of atrial tachyarrhythmias to permanent AF.

Original languageEnglish
Pages (from-to)2352-2362
Number of pages11
JournalEuropean Heart Journal
Volume35
Issue number35
DOIs
Publication statusPublished - Sep 14 2014

    Fingerprint

Keywords

  • Atrial antitachycardia pacing
  • Atrial fibrillation
  • Bradycardia
  • Managed ventricular pacing
  • Pacemaker

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Boriani, G., Tukkie, R., Manolis, A. S., Mont, L., Pürerfellner, H., Santini, M., Inama, G., Serra, P., De Sousa, J., Botto, G. L., Mangoni, L., Grammatico, A., & Padeletti, L. (2014). Atrial antitachycardia pacing and managed ventricular pacing in bradycardia patients with paroxysmal or persistent atrial tachyarrhythmias: The MINERVA randomized multicentre international trial. European Heart Journal, 35(35), 2352-2362. https://doi.org/10.1093/eurheartj/ehu165